Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2067-2077

  Tittarelli, Andrés ^a,b   González, Fermín E ^a,b   Pereda, Cristián ^a,b   Mora, Gabriela ^a,b   Muñoz, Leonel ^a   Saffie, Carlos ^a   García, Tamara ^a,b   Díaz, David ^a   Falcón, Cristián ^a,b   Hermoso, Marcela ^a   López, Mercedes N ^a,b,c   Salazar Onfray, Flavio ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Dendritic cells; Immunotherapy; Melanoma; TLR4

Indexed keywords

ASPARTIC ACID; B7 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCINE; INTERLEUKIN 6; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA VACCINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LYSATE; CELL SURFACE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; HEAT SHOCK; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TOLL LIKE RECEPTOR 4 GENE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR ALPHA GENE; VACCINE PRODUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870978203     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1268-7     Document Type: Article

References (45)

1. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419-426
2. Pasare C, Medzhitov R (2005) Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 560:11-18
3. Nembrini C, Abel B, Kopf M, Marsland BJ (2006) Strong TCR signaling, TLR ligands, and cytokines redundancies ensure robust development of type 1 effector T cells. J Immunol 176:7180-7188
4. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune response. Nat Immunol 5:987-995
5. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ (2010) Toll-like receptor expression and function in human dendritic cell subsets: Implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59:1573-1582
6. Frankenberger B, Schendel DJ (2012) Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 91:53-58
7. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552-559
8. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722-733
9. Adams S (2009) Toll-like receptor agonists in cancer therapy. Immunother 1:949-964
10. Re F, Strominger JL (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276:37692-37699
11. Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185-194
12. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059
13. Schroǒder NWJ, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156-164
14. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N et al (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 104:16645-16650
15. Santos JL, Lera L, Pérez-Bravo F, Albala C (2006) Adiposity and bone mineral density of Chilean elderly women in relation to tolllike receptor 4 gene polymorphisms. Ann Hum Biol 33:585-592
16. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Gen 25:187-191
17. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A et al (2004) Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189: 2057-2063
18. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B et al (2008) Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 154:360-364
19. Kutikhin AG (2011) Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 72:193-206
20. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pǔtter C, Wild CA et al (2011) Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 9:139
21. Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A et al (2011) Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS ONE 6:e24370
22. Escobar A, López MN, Serrano A, Ramírez M, Pérez C, Aguirre A et al (2005) Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142:555-568
23. López MN, Pereda C, Segal G, Mun?oz L, Aguilera R, González FE et al (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor bexpressing T cells. J Clin Oncol 27:945-952
24. Aguilera R, Saffie C, Tittarelli A, González FE, Ramírez M, Reyes D et al (2011) Heat-shock induction of tumor-derived danger signals mediate rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17:2474-2483
25. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S (2004) Automatic and quantitative measurement of protein-protein co localization in live cells. Biophys J 86: 3993-4003
26. Chomczynski P, Mackey K, Drews R, Wilfinger W (1997) DNAzol: A reagent for the rapid isolation of genomic DNA. Biotechniques 22:550-553
27. Figueroa C, Peralta A, Herrera L, Castro P, Gutiérrez A, Valenzuela J et al (2006) NOD2/CARD15 and Toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw 17:125-130
28. Mendoza-Naranjo A, Sáez PJ, Johansson CC, Ramírez M, Mandakovic D, Pereda C et al (2007) Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol 178:6949-6957
29. van der Graaf C, Kullberg BJ, Joosten L, Verver-Jansen T, Jacobs L, Van der Meer JW, Netea MG (2005) Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 30:264-268
30. Andrews DM, Maraskovsky E, Smyth MJ (2008) Cancer vaccines for established cancer: How to make them better? Immunol Rev 222:242-255
31. Zaloudik J, Vagunda V, Drahokoupilova M, Janakova L, Talac R, Kalabis J, Sheard M (1997) Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. Int J Immunopharmacol 19:481-485
32. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186
33. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti-and proinflammatory cytokine gene polymorphism and genetic predisposition: Association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1-8
34. Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK et al (2011) Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparinbinding hemagglutinin, a novel TLR4 agonist. Cancer Res 71:2858-2870
35. Riddell JR, Wang XY, Minderman H, Gollnick SO (2010) Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol 184:1022-1030
36. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179
37. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR (2007) Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 111:36-44
38. Casanova JL, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29: 447-491
39. Loeffler J, Ok M, Morton OC, Mezger M, Einsele H (2010) Genetic polymorphisms in the cytokine and chemokine system: Their possible importance in allogeneic stem cell transplantation. Curr Top Microbiol Immunol 341:83-96
40. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22:4717-4724
41. Ugurel S, Schrama D, Keller G, Schadendorf D, Broǒcker EB, Houben R et al (2008) Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 57:685-691
42. Tze LE, Horikawa K, Domaschenz H, Howard DR, Roots CM, Rigby RJ et al (2011) CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med 208:149-165
43. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420
44. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482-491
45. Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58: 317-324